A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas.
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2013
At a glance
- Drugs Lapatinib (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Apr 2010 Actual end date (December 2008) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.